###### Strengths and limitations of the study

-   This study used data from a large-scale multicentre registry in a contemporary era of percutaneous intervention.

-   We used propensity score matching and multivariable logistic regression model to adjust for confounders, which ensured the robustness of our conclusion.

-   The current study did not include data on patients who died before hospitalisation, which may have caused index event bias (a type of selection bias).

-   The current study did not adjust for unmeasured confounders.

Introduction {#s1}
============

Smoking is a well-established risk factor of cardiovascular disease.[@R1] However, some previous studies have shown that smokers have a better outcome than do non-smokers following acute myocardial infarction (AMI). This phenomenon is referred to as 'smoker's paradox'. This phenomenon was first introduced in the 1970s, when Helmers found that smokers had a lower risk of mortality than did non-smokers.[@R3] Some subsequent studies also showed smoker's paradox in patients with acute coronary syndrome.[@R4] This paradox may be explained by differences in baseline characteristics between smokers and non-smokers.[@R5] Additionally, the antiplatelet response may differ according to smoking status because of the effect of smoking on pharmacodynamics of clopidogrel therapy.[@R6] Notably, most studies regarding smoker's paradox were conducted in the era of thrombolysis, while the association between smoking and in-hospital mortality in patients who are treated with the percutaneous intervention (PCI) remains controversial. Some studies have reported that the difference in in-hospital mortality was not significant between smokers and non-smokers after accounting for age and other baseline characteristics.[@R7] Other studies reported that smokers had a lower in-hospital mortality rate compared with non-smokers, even after adjustment for potential confounders (smoker's paradox).[@R14]

Examining the true effect of smoking on outcome among contemporary patients with AMI is important. On one hand, the phenomenon of 'smoking paradox' has a negative effect on quitting smoking in a public health perspective. On the other hand, if smoker's paradox still exists in the contemporary era of PCI, the biochemical basis for this phenomenon should be investigated. This investigation may promote the development of novel therapy for myocardial protection.

This study aimed to assess how smoking affects the in-hospital mortality of patients receiving contemporary management of AMI.

Methods {#s2}
=======

Data source {#s2-1}
-----------

A cohort study was conducted using data from the China AMI (CAMI) registry between 01 January 2013 and 31 January 2016. A detailed description of the registry design was published previously.[@R19] Briefly, the CAMI registry was a prospective, multicentre, observational registry. The project included Chinese patients with AMI and data were collected on patients' characteristics, treatments and outcomes. A total of 108 hospitals covering a broad geographic region participated in the project. This assured a good representation of all of the patients with AMI in China and reduced selection bias.[@R19] Written informed consent was obtained from each patient who was included in the study. If the patient was not able to communicate, informed consent was obtained from a family member. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

Study population {#s2-2}
----------------

We included the study population from the CAMI registry. Eligible patients were diagnosed with AMI and within 7 days of ischaemic symptoms. Diagnostic criteria of AMI were in accordance with the third universal definition of MI.[@R20] We excluded patients who were aged \<18 or \>100 years, and those with missing or invalid data on sex, admission diagnosis and smoking status.

Data were extracted by trained researchers using standard definitions to reduce measurement and reporting bias. These data included age, sex, height, weight, clinical presentation (symptoms, ST-segment elevation, anterior wall MI, blood pressure, heart rate, heart failure, cardiac shock, fatal arrhythmia, cardiac arrest and Killip classification), risk factors (hypertension, hyperlipidaemia and diabetes), comorbidities (heart failure, peripheral vascular disease (PVD), stroke, chronic kidney disease and chronic obstructive pulmonary disease (COPD)), medical history (family history of premature coronary artery disease (CAD), prior angina or MI, prior coronary intervention and prior coronary artery bypass grafting (CABG)), initial reperfusion strategy (primary PCI, thrombolysis and conservative therapy), laboratory results (creatinine, haemoglobin and left ventricular ejection fraction (LVEF)) and in-hospital outcome.

Patient and public involvement {#s2-3}
------------------------------

We did not involve patients or the public in our work.

Definition of variables {#s2-4}
-----------------------

All patients were divided into three groups according to smoking status. Current smokers were defined as those who smoked within 1 month before registration. Ex-smokers were defined as those who quitted smoking for at least 1 month. Non-smokers were defined as those who never smoked. Standard definitions of the medical history and physical examination elements were well described in the American College of Cardiology and American Heart Association (ACC/AHA) Task Force on Clinical Data Standards and the NCDR-ACTION-GWTG element dictionary.[@R21] ECGs and echocardiograms were interpreted locally.

The primary endpoint was all-cause in-hospital mortality, which was defined as all-cause death during hospitalisation.

Statistical analysis {#s2-5}
--------------------

Baseline continuous data are presented as mean±SD or median (25th--75th percentiles) and were compared using one-way analysis of variance. This was followed by the Bonferroni t-test with a corrected p value of 0.05/3. Categorical data are presented as counts and frequencies and were compared using the χ^2^ test. Propensity score (PS) matching was used to control for baseline differences. We performed PS matching between current and non-smokers, and between ex-smokers and non-smokers. We used a multivariable logistic regression model to estimate PSs, with smoking as the dependent variable and the following factors as covariates: age, sex, body mass index (BMI), systolic blood pressure, heart rate, admission diagnosis, cardiac arrest, chest pain, ST elevation, anterior wall MI, Killip classification, risk factor (medical history of diabetes, hypertension, hyperlipidaemia, premature family CAD history, heart failure, renal failure and COPD), medical history (previous angina, PCI and CABG), creatinine levels, haemoglobin levels, Global Registry of Acute Coronary Events risk score and primary PCI. These variables were chosen as covariates because the difference in these baseline characteristics reached statistical significance or these variables were previously reported to be associated with patients' outcome.

Matching was performed using the greedy nearest matching algorithm and a 1:1 fashion. The calliper width was equal to 0.01 of the standardised difference of the score. McNemar's and paired t tests were used to compare continuous and categorical variables between the two groups after matching. For each variable in the PS model, we computed the standardised difference between the two groups, with a standardised difference less than 0.1 indicating good balance.

The stepwise selection method was used to compare in-hospital mortality across different groups. Baseline characteristics that significantly differed across the groups and those of clinical importance were included in the model. These variables were the same as those used for propensity matching. A p value\<0.1 was used as the entry criterion and \<0.05 was used as the removal criterion. To determine whether the association between smoking and in-hospital mortality varied according to baseline patients' characteristics, we performed the same multivariable logistic analysis in subgroups that were stratified by age, sex, BMI, presence or absence of hypertension, diabetes, hyperlipidaemia, heart failure, prior angina, MI or coronary intervention and admission diagnosis. A two-sided p value\<0.05 was considered significant. For the interaction test, a p value\<0.1 was considered significant. For all variables included in our study, less than 2% of the data were missing. We used complete-case analysis to deal with missing data.[@R24] Patients with missing data were excluded from the analysis. We presented data as 'counts/total numbers available (frequencies)' for categorical variables.

Results {#s3}
=======

Baseline characteristics {#s3-1}
------------------------

From 01 January 2013 to 31 January 2016, a total of 41 590 continuous patients were registered in the CAMI registry. We excluded 1178 patients aged \<18 or \>100 years, and those with missing or invalid data on sex (n=18), admission diagnosis (n=1237) and detailed smoking status (n=1543). The final cohort included 37 614 patients ([figure 1](#F1){ref-type="fig"}).

![Study flow chart. From January 2013 to January 2016, 41 590 continuous patients were registered in CAMI registry. Those aged \<18 or \>100 years (n=1178), with missing or invalid data on gender (n=18), admission diagnosis (n=1237) and detailed smoking status (n=1543) were excluded. The final cohort included 37 614 patients. CAMI, China acute myocardial infarction.](bmjopen-2019-030252f01){#F1}

Baseline characteristics before matching are presented in [table 1](#T1){ref-type="table"}. A total of 16 664 (44.3%) patients were current smokers, 843 (2.2%) quit smoking before or at 1 year, 3410 (9.1%) quit smoking after 1 year and 16 697 (44.4%) were non-smokers. Current smokers were younger (57.99±11.81 vs 66.59±11.82 years) and had a higher BMI (24.39±2.87 vs 23.98±2.95 kg/m^2^) compared with non-smokers. The proportion of men (93.7% vs 49.8%) and Killip class I (80.4% vs 71.9%) was higher in current smokers compared with non-smokers. Compared with non-smokers, current smokers were less likely to have hypertension, diabetes, heart failure, stroke or chronic kidney disease, but more likely to have hyperlipidaemia. Among ex-smokers, the proportions of male sex, hyperlipidaemia, heart failure, PVD and stroke were higher than those of current smokers. Ex-smokers also showed a trend towards old age and a low proportion of hypertension and diabetes than did current smokers, but these differences were less significant compared with the differences between current and non-smokers.

###### 

Baseline characteristics according to smoking status (before matching)

  Variable                     Current smokers (n=16 664)   Ex-smokers (n=4253)   Non-smokers (n=16 697)   P value
  ---------------------------- ---------------------------- --------------------- ------------------------ ----------
  Age (years)                  57.99±11.81                  66.49±11.50           66.59±11.82              \<0.0001
  Male                         15 616/16 664 (93.7%)        3997/4253 (94.0%)     8317/16 697 (49.8%)      \<0.0001
  BMI (kg/m^2^)                24.39±2.87                   23.95±2.84            23.98±2.95               \<0.0001
  ST elevation on ECG          12 044/16 330 (74.3%)        2725/4185 (65.7%)     10 822/16 374 (66.7%)    0.2338
  SBP (mm Hg)                  127.82±24.69                 129.71±25.17          130.58±25.97             \<0.0001
  Heart rate (bpm)             76.74±17.40                  79.85±19.82           79.47±18.89              \<0.0001
  Heart failure on admission   1851/16 608 (11.1%)          817/4227 (19.2%)      3016/16 620 (18.1%)      0.0781
  Cardiac shock                512/16 597 (3.1%)            175/4227 (4.1%)       658/16 614 (3.9%)        0.5962
  Killip classification                                                                                    \<0.0001
   I                           13 332/16 577 (80.4%)        2877/4215 (68.3%)     11 906/16 568 (71.9%)    
   II                          2272/16 577 (13.7%)          799/4215 (19.0%)      2892/16 568 (17.5%)      
   III                         472/16 577 (2.8%)            324/4215 (7.7%)       951/16 568 (5.7%)        
   IV                          501/16 577 (3.0%)            215/4215 (5.1%)       819/16 568 (4.9%)        
  Comorbidities                                                                                            
   Hypertension                7288/16 653 (43.8%)          2328/4251 (54.8%)     9434/16 693 (56.5%)      0.0401
   Hyperlipidaemia             1329/16 640 (8.0%)           367/4247 (8.6%)       1020/16 679 (6.1%)       \<0.0001
   Diabetes                    2451/16 635 (14.7%)          924/4242 (21.8%)      3893/16 672 (23.4%)      0.0295
   PVD                         100/16 611 (0.6%)            49/4234 (1.2%)        115/16 642 (0.7%)        0.0035
   Heart failure               177/16 628 (1.1%)            199/4235 (4.7%)       528/16 638 (3.2%)        \<0.0001
   Stroke                      1176/16 616 (7.1%)           570/4237 (13.5%)      1666/16 648 (10.0%)      \<0.0001
   COPD                        277/16 664 (1.7%)            191/4253 (4.5%)       277/16 697 (1.7%)        \<0.0001
   Chronic kidney disease      121/16 588 (0.7%)            103/4222 (2.4%)       257/16 612 (1.5%)        0.0001
  Smoking duration (years)     30.38±11.89                  26.86±11.99           NA                       \<0.0001
  Number of cigarettes/day     21.23±11.10                  19.13±10.93           NA                       \<0.0001
  Hb (g/L)                     142.15±17.42                 135.38±19.39          130.18±19.43             \<0.0001
  Creatinine (mg/L)            37.40±0.69                   37.40±0.46            37.42±2.04               0.1842
  Primary PCI                  8499/16 544 (51.4%)          1566/4224 (37.1%)     6369/16 579 (38.4%)      0.1084
  P2Y12 inhibitors             16 086/16 458 (97.7%)        4030/4186 (96.3%)     15 837/16 446 (96.3%)    0.9423
  GRACE risk score             151.43±33.02                 171.34±35.63          169.61±35.89             \<0.0001
  In-hospital mortality        614/16 664 (3.7%)            306/4325 (7.2%)       1450/16 679 (8.7%)       0.0015

Data are presented as mean±SD or frequencies.

BMI, body mass index; COPD, chronic obstructive pulmonary disease; GRACE, Global Registry of Acute Coronary Events; Hb, haemoglobin;NA, not available; PCI, percutaneous intervention; PVD, peripheral vascular disease; SBP, systolic blood pressure.

In-hospital outcomes {#s3-2}
--------------------

Overall, 2370 patients died before discharge. There were 614 (3.7%) deaths in the current smoker group, 306 (7.2%) deaths in the ex-smoker group and 1450 (8.7%) deaths in the non-smoker group. Causes of mortality are presented in [online supplementary table 1](#SP1){ref-type="supplementary-material"}. The unadjusted OR for in-hospital mortality was 0.4 (95% CI 0.37 to 0.44, p\<0.0001) in current smokers and 0.82 (95% CI 0.72 to 0.93, p=0.0018) in ex-smokers relative to non-smokers ([table 2](#T2){ref-type="table"}). After adjustment for potential confounders, current smoking status was significantly associated with lower in-hospital mortality relative to non-smokers (adjusted OR 0.78, 95% CI 0.69 to 0.88, p\<0.001) ([table 2](#T2){ref-type="table"}). No difference in in-hospital mortality was detected between ex-smokers and non-smokers (OR 0.89, 95% CI 0.77 to 1.04, p=0.1443).
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###### 

Association between smoking and in-hospital mortality

  Smoking status                       OR (95% CI)           P value†                                    
  ------------------------------------ --------------------- --------------------- --------------------- ----------
  Current smokers versus non-smokers   0.40 (0.37 to 0.44)   0.78 (0.69 to 0.88)   0.80 (0.69 to 0.92)   \<0.0001
  Ex-smokers versus non-smokers        0.82 (0.72 to 0.93)   0.89 (0.77 to 1.04)   1.03 (1.02 to 1.04)   0.1443

\*Adjusted for age, gender, BMI, systolic blood pressure, heart rate, admission diagnosis, cardiac arrest, chest pain, ST elevation, anterior wall MI, Killip classification, risk factor (medical history of diabetes, hypertension, hyperlipidaemia, premature family CAD history, heart failure, renal failure and COPD), medical history (previous angina, PCI and CABG), creatinine level, haemoglobin level, GRACE risk score and primary PCI. The number of patients included in the adjusted model was 37 614.

†Adjusted p value.

BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; GRACE, Global Registry of Acute Coronary Events; MI, myocardial infarction; PCI, percutaneous intervention; PS, propensity score.

PS matching {#s3-3}
-----------

Before PS matching, there were differences in almost all baseline variables among the different groups ([table 1](#T1){ref-type="table"}). To control for potential confounding, we matched 8552 current smokers with 8552 non-smokers, as well as 4142 ex-smokers and 4142 non-smokers ([online supplementary table 2](#SP1){ref-type="supplementary-material"}). The standardised differences were less than 10.0% for all variables after matching, which indicated a good match between two groups. After PS matching, current smokers still had lower in-hospital mortality than did non-smokers (5.1% vs 6.1%, p=0.0045), but the difference in in-hospital mortality was not significant between ex-smokers and non-smokers (7.0% vs 7.4%, p=0.5198) ([online supplementary table 3](#SP1){ref-type="supplementary-material"}).

Subgroup analysis {#s3-4}
-----------------

Subgroup analysis indicated significant interactions between smoking status and age (p~interaction~: 0.0986), sex (p~interaction~: 0.0163), LVEF (p~interaction~: 0.0149), previous MI (p~interaction~: 0.0557) and previous heart failure (p~interaction~: 0.0086) for in-hospital mortality ([table 3](#T3){ref-type="table"}). However, there was a trend towards lower in-hospital mortality in the current or ex-smoker group compared with the non-smoker group.

###### 

Association between smoking and in-hospital mortality according to baseline characteristics

  Baseline characteristics   Current smoker        Ex-smoker             Non-smoker   P~interaction~ value
  -------------------------- --------------------- --------------------- ------------ ----------------------
  Age≥55 years               0.78 (0.69 to 0.89)   0.90 (0.77 to 1.05)   Reference    0.0986
  Age\<55 years              0.72 (0.53 to 0.99)   0.85 (0.48 to 1.49)   Reference    
  Male                       0.78 (0.68 to 0.89)   0.94 (0.80 to 1.10)   Reference    0.0163
  Female                     0.75 (0.58 to 0.98)   0.45 (0.26 to 0.77)   Reference    
  BMI≥24 kg/m^2^             0.80 (0.67 to 0.94)   0.89 (0.71 to 1.12)   Reference    0.2063
  BMI\<24 kg/m^2^            0.74 (0.63 to 0.88)   0.89 (0.73 to 1.10)   Reference    
  LVEF≥50%                   0.77 (0.67 to 0.88)   0.98 (0.82 to 1.16)   Reference    0.0149
  LVEF\<50%                  0.87 (0.68 to 1.11)   0.74 (0.54 to 1.01)   Reference    
  Hypertension---Yes         0.85 (0.72 to 1.00)   0.96 (0.78 to 1.17)   Reference    0.4556
  Hypertension---No          0.70 (0.59 to 0.83)   0.80 (0.64 to 1.01)   Reference    
  Previous angina---Yes      0.84 (0.65 to 1.07)   0.83 (0.62 to 1.12)   Reference    0.1833
  Previous angina---No       0.76 (0.66 to 0.87)   0.92 (0.78 to 1.10)   Reference    
  Previous MI---Yes          0.67 (0.47 to 0.97)   0.67 (0.45 to 1.00)   Reference    0.0557
  Previous MI---No           0.77 (0.68 to 0.87)   0.91 (0.78 to 1.07)   Reference    
  Previous PCI---Yes         0.95 (0.44 to 2.04)   1.23 (0.56 to 2.72)   Reference    0.7975
  Previous PCI---No          0.78 (0.69 to 0.88)   0.89 (0.76 to 1.04)   Reference    
  Previous HF---Yes          0.96 (0.57 to 1.60)   0.85 (0.53 to 1.37)   Reference    0.0086
  Previous HF---No           0.77 (0.68 to 0.87)   0.88 (0.76 to 1.03)   Reference    
  Diabetes---Yes             0.78 (0.60 to 1.02)   0.86 (0.63 to 1.18)   Reference    0.4065
  Diabetes---No              0.77 (0.67 to 0.88)   0.90 (0.76 to 1.07)   Reference    
  Hyperlipidaemia---Yes      0.75 (0.45 to 1.24)   1.16 (0.66 to 2.03)   Reference    0.1239
  Hyperlipidaemia---No       0.77 (0.68 to 0.87)   0.87 (0.74 to 1.02)   Reference    
  Diagnosis of STEMI         0.81 (0.71 to 0.93)   0.93 (0.78 to 1.11)   Reference    0.9700
  Diagnosis of NSTEMI        0.61 (0.48 to 0.78)   0.71 (0.54 to 0.92)   Reference    

Adjusted for age, gender, BMI, systolic blood pressure, heart rate, admission diagnosis, cardiac arrest, chest pain, ST elevation, anterior wall MI, Killip classification, risk factor (medical history of diabetes, hypertension, hyperlipidaemia, premature family CAD history, heart failure, renal failure and COPD), medical history (previous angina, PCI and CABG), creatinine level, haemoglobin level, GRACE risk score and primary PCI.

BMI, body mass index;CABG, coronary artery bypass grafting; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; GRACE, Global Registry of Acute Coronary Events; HF, heart failure; LVEF, left ventricular ejection fraction; MI, myocardial infarction;NSTEMI, non-ST-elevation MI; PCI, percutaneous coronary intervention; STEMI, ST-elevation MI.

Discussion {#s4}
==========

Our study used data from the CAMI registry, which is the largest contemporary registry of patients with AMI in East Asia. Our major finding was that in patients with AMI, current smokers had lower in-hospital mortality than did non-smokers in the whole population and almost all subgroups, after adjusting for potential confounders using PS matching.

Comparison with previous studies {#s4-1}
--------------------------------

Most previous studies were conducted in the thrombolytic era and we only identified four studies that enrolled patients in the current primary PCI era.[@R13] Of these four studies, three studies used multivariate regression analysis to control for confounders. Our study results are consistent with those from another large-scale study.[@R18] This previous study also showed that among patients with ST-elevation MI who received primary PCI, smokers (including current and ex-smokers) had a lower adjusted in-hospital mortality risk than did non-smokers. In our study, we further separated current and ex-smokers, and used PS matching to comprehensively control for potential confounders. Several mechanisms have been proposed to explain this paradox phenomenon.

First, some studies showed that a suppressive effect of clopidogrel on platelets was greater in smokers than in non-smokers.[@R27] A potential explanation for this finding is that smoking can enhance in-vivo bioactivation of clopidogrel via increasing induction of cytochrome P450 (CYP1A2 and CYP2B6) and increased active metabolite concentrations of clopidogrel.[@R30] Therefore, smokers may respond better to clopidogrel therapy and consequently have a lower in-hospital mortality rate than non-smokers. Second, smoking was unexpectedly associated with a lower risk of adverse left ventricular remodelling postinfarction. Symons *et al* performed cardiac MRI at 4 days and 4 months after MI. They found that smokers had an improved LVEF, which was attributable to a decrease in the end-diastolic volume index, but not an increase in the systolic volume index.[@R32]

However, our results are not consistent with two studies, which found an absence of the smoker paradox after baseline risk adjustment.[@R13] This difference may be related to the selection of the study population and sample size. One previous study enrolled patients with symptomatic CAD, including those who presented with stable or unstable angina,[@R9] while we included patients with AMI. Patients with stable angina represent a relatively lower risk group. Therefore, enrolment of this patient subset may affect the association between smoking and mortality. The other study had a small sample size (n=382), and it may not have had sufficient statistical power to detect a difference in mortality between smokers and non-smokers.

Interpretation of our results {#s4-2}
-----------------------------

Our results should be interpreted with caution. Although we adjusted for many common confounders, our study was still subject to selection bias as discussed below in the Strengths and limitations of the study box. Our results should not be interpreted as encouraging patients to smoke. Smoking is well-established as an independent risk factor for mortality and recurrent MI,[@R33] as well as for subacute stent thrombosis[@R34] in the long-term, and patients with coronary heart disease can benefit from cessation of smoking.[@R35] Therefore, we still recommend that patients stop smoking. Our results indicated potential mechanisms underlying the protective effect of smoking. Future studies should investigate novel therapies to protect the myocardium by targeting the relevant pathways. Smoking might lead to a chronic ischaemic state (ischaemic preconditioning)[@R36]; therefore, smokers might have better tolerance for an acute ischaemic event, such as a heart attack. The phenomenon could be investigated by examining whether preconditioning therapy or a brief period of reversible ischaemia can protect the myocardium and improve outcome.

Our subgroup analysis showed a significant interaction between smoking status and age, sex, LVEF, previous MI and previous heart failure. However, currently, we cannot reach the conclusion that these baseline characteristics had a significant effect on the relationship between smoking and in-hospital mortality. This is because there was a similar trend among all subgroups that current smokers and ex-smokers had a lower in-hospital mortality risk compared with non-smokers. A significant p value may be attributed to a different OR value between subgroups of smokers and non-smokers, as well as a large sample size of some of the subgroups.

Limitations {#s4-3}
-----------

Our study may have been subject to selection bias. The CAMI registry did not collect data on patients who died before hospitalisation. Failing to account for prehospital deaths may have led to selection bias. The distribution of risk factors was significantly different between smokers and non-smokers. Although we adjusted for known and measured variables, there are likely to be other unmeasured variables leading to selection bias. The CAMI registry was a multicentre, large-scale study that involved more than 100 hospitals. Although a standardised data collection procedure was emphasised, the accuracy of data still greatly depends on the expertise of local investigators. The CAMI registry did not collect detailed data regarding the smoking status. Smoking status might be modified after the onset of MI. However, we asked the patients about their smoking status before the onset of AMI and all patients were enrolled within 7 days of symptom onset. We only assessed the association between smoking and short-term outcome. Future studies are required to investigate this association in the long-term.

Conclusions {#s5}
===========

Our study showed that the in-hospital mortality rate was lower in smokers compared with non-smokers in a large-scale, contemporary cohort representing patients with AMI in China. Our findings indicate that future studies should be performed to further explore the potential biological mechanisms that may explain this phenomenon.
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